Analysis File of Drug-Induced Lung Injury

Dekorationsartikel gehören nicht zum Leistungsumfang.

Sprache: Englisch

108,95 €

inkl. MwSt.

Versandkostenfrei per Post / DHL

Lieferzeit 1-2 Wochen

Kategorien:

Beschreibung

This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.

Über den Autor

¿Akihiko Gemma

President, Nippon Medical School

1983: Graduated from the Faculty of Medicine of Nippon Medical School

1986: Served as a trainee doctor in the Pathology Department of the National Cancer Center Research Institute

1989: Graduated from Nippon Medical School Graduate School

1995: Studied at National Cancer Institute of National Institutes of Health (NIH), the United States

1998: Appointed as a lecturer to Nippon Medical School

2004: Appointed as an associate professor

2008: Appointed as a senior professor to the Department of Medicine (Respiratory, Infectious Disease and Oncology Division)

2012: Appointed as a professor to the Graduate School of Medicine in charge of respiratory medicine

2013: Appointed dean of Department of Medicine

2015¿ Appointed president

Inhaltsverzeichnis

Part I Understanding Drug-Induced Lung Injuries.- 1 Understanding Drug-Induced Lung Injuries.- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug.- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib).- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab).- 4 mTOR inhibitors (temsirolimus, everolimus).- 5 Proteasome inhibitor (bortezomib).- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab).- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab).- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.).- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan).- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).

Details

Erscheinungsjahr:	2024
Fachbereich:	Andere Fachgebiete
Genre:	Importe , Medizin
Rubrik:	Wissenschaften
Medium:	Buch
Inhalt:	xii 116 S. 30 s/w Illustr. 18 farbige Illustr. 116 p. 48 illus. 18 illus. in color.
ISBN-13:	9789819734450
ISBN-10:	9819734452
Sprache:	Englisch
Einband:	Gebunden
Autor:	Gemma, Akihiko
Hersteller:	Springer Springer Singapore Springer Nature Singapore
Verantwortliche Person für die EU:	Springer Verlag GmbH, Tiergartenstr. 17, D-69121 Heidelberg, juergen.hartmann@springer.com
Maße:	241 x 160 x 13 mm
Von/Mit:	Akihiko Gemma
Erscheinungsdatum:	02.08.2024
Gewicht:	0,389 kg